← Back to Search

Other

Microdosing + Meditation for Healthy Adults (OMM Trial)

N/A
Waitlist Available
Led By Matthew Hicks, ND, MS
Research Sponsored by National University of Natural Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to read and speak fluent English
Age 21 or older - Oregon Psilocybin Services Act sets the minimum eligible age of 21
Must not have
Uncontrolled hypertension or heart disease
Active cancer treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of approval to completion of the study, up to one year.
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to see if combining meditation with psilocybin microdosing is feasible and safe for healthy adults. They want to find out if they can recruit and retain participants, and if the

Who is the study for?
This trial is for healthy adults interested in combining meditation with psilocybin microdosing. Participants must be willing to use the Oura Ring to monitor biometrics and complete quality of life assessments. Details on specific inclusion or exclusion criteria are not provided.
What is being tested?
The study tests if it's feasible to combine meditation with psilocybin microdosing. All participants will try microdoses of psilocybin, but only half, chosen randomly, will also practice meditation. The trial measures recruitment success, participant retention, safety, tolerability, and various health outcomes.
What are the potential side effects?
While specific side effects are not listed for this trial, common side effects of psilocybin may include changes in sensory perception, mood alteration, nausea, headache or fatigue. Meditation is generally considered safe but can sometimes cause discomfort when dealing with personal issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can read and speak English fluently.
Select...
I am 21 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have uncontrolled high blood pressure or heart disease.
Select...
I am currently receiving treatment for cancer.
Select...
I or an immediate family member have a history of schizophrenia, psychosis, mania, or hypomania.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~collected at all study events, up to one year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and collected at all study events, up to one year. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability
Recruitment and Retention Feasibility
Safety and Tolerability
Other study objectives
Altered states of consciousness
Objective Sleep quality and duration
Qualitative data
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Microdosing plus meditationExperimental Treatment2 Interventions
Group II: Microdosing onlyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psilocybin
2021
Completed Phase 2
~530
Meditation
2021
Completed Phase 3
~2940

Find a Location

Who is running the clinical trial?

National University of Natural MedicineLead Sponsor
31 Previous Clinical Trials
1,255 Total Patients Enrolled
Matthew Hicks, ND, MSPrincipal InvestigatorNational University of Natural Medicine
~16 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top